The Presence of Pronounced Mental Health Infrastructure is Escalating the European Schizophrenia Drugs Market

The European schizophrenia drug market is projected to grow at a significant CAGR of around 2.5% during the forecast period (2020-2026). The availability of considerable resources for mental health and a sophisticated healthcare system are other key factors that are expected to promote the growth of the market. In the UK, Mental Health First Aid (MHFA) England, a social organization that offers expert guidance and training to support mental health, estimated in 2019 that nearly one in four people face mental health issues each year and are responsible for 72 million working days lost and costs $45.5 billion each year. Therefore, a significant market is estimated in Europe for schizophrenia drugs.

Browse the full report description of "European Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Therapeutic Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, and Others) and by Treatment (Oral and Injectables) and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/european-schizophrenia-drugs-market

Further, according to the WHO, almost 83 million people are affected annually by mental disorders among the adult population of Europe (aged 18-65), where female rates are higher than males. This involves the high demand for products which can bring down the level of schizophrenia among people. According to the Institute for Health Metrics and Evaluation (IHME), the EU spent an average of $22 per capita on mental health programs and services in 2016. Nearly all the countries in the European region had a stand-alone or integrated mental health policy or plan. This can be considered as another factor for the substantial growth of the market in the region.

Market Coverage

Key questions addressed by the report

• What is the market growth rate during the forecast period?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market during the forecast period?
• How COVID-19 will impact the market growth in 2020 and coming years?

o Recovery Timeline

o Deviation from pre-COVID-19

o Most affected region/segment

o Recommendations 

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

European Schizophrenia Drugs Market – Segmentation

By Therapeutic Class

• Second Generation Antipsychotics 
• Third Generation Antipsychotics
• Others (First Generation Antipsychotics)

By Treatment

• Oral 
• Injectables

European Schizophrenia Drugs Market – Segmentation by Geography

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe